This article has an erratum: [https://doi.org/10.1051/mbcb/2023035]
J Oral Med Oral Surg
Volume 29, Number 3, 2023
|Number of page(s)
|31 August 2023
Management of biologics in oral surgery
Department of Oral and Maxillofacial Surgery, Norfolk and Norwich University Hospital, UK
* Correspondence : firstname.lastname@example.org
Accepted: 11 July 2023
Biologics have revolutionised the management of immune-mediated inflammatory disorders, and their growing use has resulted in increasing numbers of these patients presenting in oral surgery settings. While the efficacy of biologics has been well established, they are associated with numerous adverse effects. Several professional bodies have published recommendations on perioperative management of these agents to reduce complications. Currently no specific dental or oral surgery guidance exists. The aim of this paper is to review the current literature and guidance regarding the use of biologics in the perioperative period.
Key words: Biological products / infections / oral surgical procedures / oral surgery / postoperative complications
© The authors, 2023
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.